A recent study by researchers at the University of Oxford has highlighted the importance of providing continuous support to individuals utilizing weight loss injections, as findings revealed that they tend to regain lost weight much quicker than those following traditional diet plans. The study focused on medications such as semaglutide (Wegovy) and tirzepatide (Mounjaro), showing that although weight loss is achieved during treatment, the weight is typically regained within 20 months after discontinuing the injections.
Moreover, the study indicated that improvements in blood sugar levels, cholesterol, and blood pressure seen during treatment diminish once individuals stop taking the drugs, resulting in a return to their initial weight and health status. In contrast, individuals who adopt healthier eating habits and engage in regular exercise tend to maintain weight loss for approximately four years before regaining it gradually.
Separately, research conducted by University College London (UCL) and the University of Cambridge raised concerns about potential nutritional deficiencies and muscle loss among individuals prescribed newer weight loss medications. While Wegovy is currently limited to a two-year NHS prescription, there are no restrictions on Mounjaro. The majority of individuals using these medications opt for private payment due to limited NHS access.
The Oxford study, published in the British Medical Journal (BMJ), analyzed data from 37 studies involving over 9,000 participants, with an average treatment period of 10 months and follow-up of eight months. Overall, individuals on weight loss medication experienced an average weight loss of 8.3kg during treatment but regained 4.8kg within the first year, ultimately returning to their initial weight within 1.7 years post-treatment. Specifically, those on Wegovy and Mounjaro lost nearly 15kg but regained 10kg within the first year after treatment cessation.
Lead researcher Susan Jebb emphasized the rapid and common nature of weight regain post-medication, stressing the need for a long-term approach to managing obesity through sustained interventions such as medication, behavioral changes, or a combination of both. She highlighted the chronic nature of obesity, suggesting that treatments should be continued indefinitely, akin to managing conditions like high blood pressure.
Jebb further recommended integrating behavioral programs alongside drug treatments to enhance weight loss maintenance. However, she cautioned that these strategies might not suffice once medication is discontinued. The study indicated that individuals may explore intermittent treatment or behavior support to sustain weight loss, but the most effective long-term approach remains uncertain.
In conclusion, the study team underscored the necessity for prolonged use of weight management medications to maintain health benefits in individuals struggling with obesity. Further research is warranted to explore strategies for promoting effective use of these drugs, potentially through continuous adherence or intermittent treatment periods.